| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
In order to offer our patients even more solutions tailored to their needs, continuous improvement treatments and technologies is at the heart of the concerns of the ovo clinic.
All our doctors regularly contribute to the advancement of research through the publication of articles and results of clinical studies in scientific journals internationally recognized. They are also involved in the training of fellows and oversee the development of their clinical skills, research and teaching.
Voyage d'études et de rencontres
JTA - Journées de techniques avancées
ovo acédemie et Pax Medicalis ont le plaisir de vous convier à un voyage en Israël où se mêlent science, histoire et traditions. En plus de visiter de nombreux lieux de santé (comme le centre de dépistage des cardiopathies foetales à Hébron et la maternité Saint Joseph à Jérusalem), ce voyage du 5 mai au 14 mai 2019 est l’occasion d’aborder de nombreuses thématiques comme “l’éthique, la médecine et la religion : début et fin de vie” ou encore “l’environnement, le réchauffement climatique, les perturbateurs endocriniens…” etc. !
L’objectif principal de ce congrès est de rassembler plusieurs professionnels de différentes disciplines, jusque là peu habitués à travailler conjointement, dans le but de transférer de nouvelles technologies.
Patient Support
Educational group sessions are available to understand your specific protocol and share your experience with other patients.
For patients who wish, individual training is also available for self-medication to teach you how to give yourself an injection in the comfort of your home and give you helpful tips for treatments.
Professional Support
Based on their experience, the ovo clinic and ovo r&d offer training workshops for professionals, pharmaceutical companies and public health agencies involved in the conduct of clinical studies that wish to ensure compliance and patient safety in all their clinical research projects and implementing exceptional standards of quality in order to obtain the certifications of compliance from Health Canada.
These professional workshops offer the opportunity to develop your teams on specific topics such as regulatory practices, project management, compliance with good clinical practice and ethical principles in research.
Préservation de la fertilité : chez les femmes atteintes de cancer
Bulletin scientifique de la clinique ovo
vol. 10, mars 2016
Dr Hady El Hachem
Dr Karen Buzaglo
Dr Coralie Beauchamp
Dr Camille Sylvestre
Dr Louise Lapensée
Toute patiente en âge de procréer avec un diagnostic récent de cancer doit être informée du risque d’infertilité secondaire au traitement anticancéreux, et doit être référée à un spécialiste en endocrinologie de la reproduction, avant l’initiation des traitements, pour une consultation d’oncofertilité dans le but de discuter d’un éventuel recours à des techniques de préservation de la fertilité.
Préservation de la fertilité : pour déplétion anticitée des gamètes
The ovo clinic's scientific bulletin
vol. 9, february 2015
Dr Hady El Hachem
Dr Coralie Beauchamp
Dr Karen Buzaglo
Dr Marie-Alexia Allard
Dr Louise Lapensée
Le désir tardif d’avoir un enfant est un phénomène courant dans notre société. Comme gynécologues, nous nous devons de continuer à propager le message que la fertilité diminue progressivement avec l’âge, et ceci à cause d’une diminution quantitative et qualitative de la réserve ovarienne.
Plusieurs femmes et couples sont incapables ou ne désirent pas réaliser un projet familial à un âge relativement jeune. La préservation de fertilité par vitrification des ovules peut s’avérer une option intéressante dans ces cas.
Syndrome de Turner:
procréation et grossesse
The ovo clinic’s scientific bulletin
vol. 8, december 2014
Dr Pierre-Emmanuel Bouet
Dr Ariane Godbout
Dr Maude Lefebvre
Dr Lyne Bérubé
Dr Marie-Danielle Dionne
Dr Carole Kamga-Ngande
Dr Louise Lapensée
Caractérisé par une dysgénésie ovarienne associée à un nombre variable d’anomalies extra-gonadiques, le syndrome de Turner (ST) nécessite une prise en charge multidisciplinaire afin d’optimiser les soins.
La prise en charge dès l’enfance et l’adolescence des femmes avec ST permet la compensation précoce de l’hypogonadisme.
Obesity and Fertility
The ovo clinic's scientific bulletin
vol. 7, february 2012
Dr Carole Kamga
Dr Louise Lapensée
Obesity remains to be studied as to its implications in fertility troubles. In Canada, recent estimations show that 24.3% of males and 23.8% of females are obese. Women between the age of 20 and 39 show the highest growth in the obesity demographic.
Stem cells:
a therapeutic revolution
The ovo clinic’s scientific bulletin
vol. 6, december 2010
Dr Jacques Kadoch
Dr Robert Hemmings
Dr Marinela Mandra
Since the first successful transplant in 1998, about 20,000 transplants were performed in total according to the Stem Cell Summit Report in 2009.
Currently, about 3,000 transplants are performed each year. Thus, transplantation of cord blood has become a medical standard.
Oncology and fertility
preservation
The ovo clinic’s scientific bulletin
vol. 5, november 2008
Dr Bernard Couturier
Some cancer treatments can cause reduced fertility or infertility. According to the different scenarios, it would be wise to consider a specific support for fertility preservation for cancer patients.
Genetic and infertility
The ovo clinic’s scientific bulletin
vol. 4, february2007
Dr Régen Drouin
One couple out of seven will have a decrease in fertility. In 40% of cases, the men will be responsible for this decrease; in 40% of cases, the women will be responsible and in the 20% left, it will be a combination of causes involving both partners.
Male infertility
evaluation
The ovo clinic’s scientific bulletin
vol. 3, december 2005
Dr Jacques Kadoch
Dr Robert Hemmings
In North America, 15% of all couples are infertile. When broken down into statistics, an abnormality is found in only the man in 30% of the cases, while abnormalities detected in both partners occur in another 20%. Therefore, male factor infertility accounts for one half of couple with fertility problems.
Polycystic ovarian
disease
The ovo clinic’s scientific bulletin
vol. 2, november2004
Dr Jacques Kadoch
Dr Robert Hemmings
The Polycystic ovarian syndrome (P.C.O.S.) is a condition characterized by ovaries with multiple small follicles which do not mature to a dominant size leading to ovulation.
This is one of the leading causes of infertility. A recent international consensus has emerged on P.C.O.S..
Prenatal diagnosis
The ovo clinic’s scientific bulletin
vol. 2, may 2004
Dr François Bissonnette
Dr Bernard Couturier
Dr Robert Hemmings
Dr Louise Lapensée
Chromosomal abnormalities constitute one of the most important causes of perinatal mortality and neonatal morbidity. With an incidence of approximately
1 / 700, trisomy 21 (Down syndrome) is by far the most common chromosomal anomaly. These children have an average IQ of 40 and a very high risk of dementia (40 %).
